Angel Pharmaceuticals is focused on developing innovative medicines to improve the lives of cancer patients, particularly in the Chinese market. The company has a robust pipeline of therapies, including CPI-818, the world's first ITK inhibitor, which targets T-cell lymphomas and autoimmune diseases. This drug works by inhibiting the Interleukin-2 Inducible T-cell Kinase (ITK), enhancing the immune response and potentially controlling cancer cell survival. CPI-818 has received FDA approval to enter Phase III clinical trials for relapsed/refractory peripheral T-cell lymphoma, with promising preliminary results presented at major oncology conferences.

In addition to CPI-818, Angel Pharmaceuticals is advancing other significant therapies such as CPI-006, a humanized monoclonal antibody that activates B-cells to combat solid tumors, and ANG-0623, a third-generation BTK inhibitor with potential applications in central nervous system diseases. The company is also developing Ciforadenant (CPI-444), an adenosine A2A receptor antagonist aimed at renal cell carcinoma and multiple myeloma, which has shown efficacy in early clinical trials. These innovative treatments reflect Angel Pharmaceuticals' commitment to sustainable innovation and improving patient outcomes in oncology and autoimmune diseases.

China

Angel Pharmaceuticals was founded in 2020, focusing on develop, produce and sale of innovative oncology drugs. We develop four innovative drugs in China and build a platform for new drugs, aiming at the unmet medical needs of China's cancer drug market, and build China's first-class innovative drug company. Our management team has decades of clinical and drug research and development experience, which lays a solid foundation for the development of new drugs.

Angel Pharmaceuticals

Company Details